Company Directory

Generative AI platform for TCR therapy design and immune repertoire analysis

Synteny Biotechnology is a biotechnology company developing a platform that combines high-throughput TCR-antigen data generation with generative AI to design precision T cell receptor therapies for cancer. The platform addresses a critical bottleneck in the field, namely the scarcity of paired TCR-epitope interaction data, using protein language models to engineer TCRs with improved tumour specificity and reduced cross-reactivity. The company applies this platform to an internal pipeline of TCR bispecific therapeutic candidates.

Synthetic promoter platform for precision gene expression control

Chromatin Bioscience designs synthetic promoters and gene expression control systems for cell and gene therapy developers. Its platform uses bioinformatics to identify cell-type-selective regulatory elements from the human genome, which are assembled into novel synthetic promoters enabling precise, durable and targeted transgene expression. The company's promoters are integrated into partner programmes across oncology, nephrology and rare disease gene therapies, with a clinical-stage collaboration supporting an in vivo CAR-T candidate for multiple myeloma.

Next-generation lateral CAR-T therapies for refractory solid tumours

Leucid Bio Ltd is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for hard-to-treat solid tumours. Founded on over two decades of King's College London research, the platform redesigns the CAR signalling architecture to enhance T-cell potency, persistence, and tumour infiltration. Lead asset LEU011 targets NKG2D stress ligands expressed on over 80% of human tumours and is being evaluated in the Phase I/IIa AERIAL multi-centre dose-escalation trial, manufactured at Great Ormond Street Hospital's GMP facilities.

Target discovery platform and antibody-based therapies for oncology

Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies, T-cell engagers, and CAR-T targets. The company licenses discovered targets and development candidates to major pharmaceutical partners including Bristol Myers Squibb, Roche, GSK, and Boehringer Ingelheim.

Robotic automation platform for scalable cell therapy manufacturing

Cellular Origins is a biotechnology company developing robotic automation systems for the industrial-scale manufacture of cell therapies. Its platform uses mobile robotics and automated sterile fluidic interconnection to link existing bioprocess instruments into fully automated, GMP-compliant manufacturing workflows. The platform is designed to scale production without requiring therapy redevelopment or process change. Cellular Origins partners with cell therapy developers and equipment manufacturers including Cytiva, Fresenius Kabi and Thermo Fisher Scientific.

Engineered T cell receptor therapies for solid tumour cancers

Adaptimmune is a clinical-stage biopharmaceutical company developing engineered T cell receptor therapies targeting solid tumours. The company's T-cell platform engineers T cell receptors with enhanced affinity for cancer-associated antigens, enabling immune recognition of tumour cells that evade conventional therapies. Adaptimmune received FDA approval for its lead therapy in synovial sarcoma in 2024, the first approved T cell therapy for a solid tumour. The company is headquartered in Philadelphia with UK research operations at Milton Park.

Global supplier of instruments and reagents for cell research and therapy

Miltenyi Biotec is a company developing and supplying instruments, reagents and services supporting biomedical research and cell and gene therapy manufacturing. Its product portfolio spans magnetic-activated cell separation, flow cytometry, cell culture, molecular analysis and preclinical imaging, with clinical-grade systems including automated cell processing platforms widely used in transplantation and CAR-T cell manufacturing. Founded in Germany in 1989, the company operates a UK subsidiary and serves academic, clinical and biopharmaceutical customers across the country.

Programmable gene control platform for advanced cell therapies

Laverock Therapeutics is a biotechnology company developing a programmable gene control platform for the creation of disease-responsive advanced therapies. The platform uses recoded microRNAs to deliver tunable, stable and multiplexed gene silencing within cell therapies, enabling enhanced precision and improved safety profiles. Laverock's internal pipeline targets oncology and genetic medicine, with lead programmes in T-cell and macrophage immunotherapy.

AI-driven T-cell receptor discovery platform for solid tumour immunotherapies

Exogene is an Oxford biotech developing TCR-based immunotherapies for solid tumours. Its platform integrates generative AI, biophysical simulation, and high-throughput TCR-antigen screening to identify rare, high-affinity cancer-specific T-cell receptors from patient tumour samples. The company develops TCR-T cell therapies in which patient-derived T cells are genetically reprogrammed with engineered TCRs and reintroduced to eliminate cancer cells, with a lead programme targeting non-small cell lung cancer. Exogene has a research collaboration with Immunocore.

Combinatorial stem cell screening platform for therapy development

Plasticell is a biotechnology company developing cell and gene therapies and enabling drug discovery through its proprietary platform. The technology uses bead-based combinatorial screening to test thousands of cell culture variable combinations in parallel, identifying optimised protocols for stem cell expansion, directed differentiation, and gene transduction. Applications span hematopoietic stem cell therapy, manufacture of blood cell types from iPSCs, and provision of rare human cells for pharmaceutical screening programmes.

Specialist oncology clinical trial management for biotech and pharma

Karma Oncology is a specialist contract research organisation providing full-service and functional clinical trial management to biotechnology and pharmaceutical companies in oncology. Operating as a lean virtual CRO, the company offers clinical development planning, protocol design, site selection and activation, regulatory submissions, patient recruitment, and clinical monitoring. The team has experience across solid tumours, haematological malignancies, checkpoint inhibitors, and cell therapy programmes including CAR-T.

Bispecific TCR therapies targeting HLA-Class II cancer antigens

Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to selectively eliminate cancer cells while sparing healthy tissue. Yellowstone draws on a proprietary biobank of samples from over 3,000 AML patients assembled over two decades of research at the University of Oxford.